{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T12:09:14Z","timestamp":1790683754318,"version":"4.1.0"},"reference-count":51,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2012,5,29]],"date-time":"2012-05-29T00:00:00Z","timestamp":1338249600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Bone Miner Metab"],"published-print":{"date-parts":[[2012,9]]},"DOI":"10.1007\/s00774-012-0349-1","type":"journal-article","created":{"date-parts":[[2012,5,28]],"date-time":"2012-05-28T06:25:44Z","timestamp":1338186344000},"page":"493-503","source":"Crossref","is-referenced-by-count":39,"title":["Time to onset of efficacy in fracture reduction with current anti-osteoporosis treatments"],"prefix":"10.1007","volume":"30","author":[{"given":"Charles A.","family":"Inderjeeth","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kien","family":"Chan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin","family":"Kwan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle","family":"Lai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2012,5,29]]},"reference":[{"key":"349_CR1","unstructured":"World Health Organisation (2004) WHO Technical report series, no. 921"},{"key":"349_CR2","volume-title":"The burden of brittle bones: costing osteoporosis in Australia","author":"Access Economics","year":"2001","unstructured":"Economics Access (2001) The burden of brittle bones: costing osteoporosis in Australia. Access Economics Pty Ltd, Canberra"},{"key":"349_CR3","doi-asserted-by":"crossref","unstructured":"Cooper C (1997) The crippling consequences of fractures and their impact on quality of life. Am J Med 103:12S\u201317S (discussion 17S\u201319S)","DOI":"10.1016\/S0002-9343(97)90022-X"},{"key":"349_CR4","doi-asserted-by":"crossref","first-page":"1969","DOI":"10.1359\/jbmr.040905","volume":"19","author":"J Eisman","year":"2004","unstructured":"Eisman J, Clapham S, Kehoe L (2004) Australian BoneCare Study. Osteoporosis prevalence and levels of treatment in primary care: the Australian BoneCare Study. J Bone Miner Res 19:1969\u20131975","journal-title":"J Bone Miner Res"},{"key":"349_CR5","doi-asserted-by":"crossref","first-page":"489","DOI":"10.5694\/j.1326-5377.2003.tb05653.x","volume":"179","author":"MN Chilov","year":"2003","unstructured":"Chilov MN, Cameron ID, March LM (2003) Australian National Health and Medical Research Council. Evidence-based guidelines for fixing broken hips: an update. Med J Aust 179:489\u2013493","journal-title":"Med J Aust"},{"key":"349_CR6","doi-asserted-by":"crossref","first-page":"S18","DOI":"10.5694\/j.1326-5377.2004.tb05908.x","volume":"180","author":"TV Nguyen","year":"2004","unstructured":"Nguyen TV, Center JR, Eisman JA (2004) Osteoporosis: underrated, under diagnosed and undertreated. Med J Aust 180:S18\u2013S22","journal-title":"Med J Aust"},{"key":"349_CR7","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1359\/jbmr.2000.15.4.721","volume":"15","author":"CM Klotzbuecher","year":"2000","unstructured":"Klotzbuecher CM, Ross PD, Landsman PB, Abbott TA 3rd, Berger M (2000) Patients with prior fractures have an increased risk of future fractures: a summary of the literature and statistical synthesis. J Bone Miner Res 15:721\u2013739","journal-title":"J Bone Miner Res"},{"key":"349_CR8","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1016\/S0140-6736(02)08827-X","volume":"359","author":"PD Delmas","year":"2002","unstructured":"Delmas PD (2002) Treatment of postmenopausal osteoporosis. Lancet 359:2018\u20132026","journal-title":"Lancet"},{"key":"349_CR9","doi-asserted-by":"crossref","first-page":"S4","DOI":"10.5694\/j.1326-5377.2004.tb05762.x","volume":"180","author":"PM Brooks","year":"2004","unstructured":"Brooks PM, Hooper MJ, Smallwood RA (2004) Bone and joint disease: prevention and control. Med J Aust 180:S4\u2013S5","journal-title":"Med J Aust"},{"key":"349_CR10","first-page":"111","volume":"33","author":"P Philips","year":"2004","unstructured":"Philips P, Braddon J (2004) Osteoporosis\u2014diagnosis, treatment and management. Aust Fam Physician 33:111\u2013119","journal-title":"Aust Fam Physician"},{"key":"349_CR11","doi-asserted-by":"crossref","first-page":"298","DOI":"10.5694\/j.1326-5377.2004.tb05931.x","volume":"180","author":"E Seeman","year":"2004","unstructured":"Seeman E, Eisman JA (2004) Treatment of osteoporosis: why, whom, when and how to treat. The single most important consideration is the individual\u2019s absolute risk factor. Med J Aust 180:298\u2013303","journal-title":"Med J Aust"},{"key":"349_CR12","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1001\/jama.285.3.320","volume":"285","author":"R Lindsay","year":"2001","unstructured":"Lindsay R, Silverman SL, Cooper C, Hanley DA, Barton I et al (2001) Risk of new vertebral fracture in the year following a fracture. JAMA 285:320\u2013323","journal-title":"JAMA"},{"key":"349_CR13","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1016\/S0140-6736(96)07088-2","volume":"348","author":"DM Black","year":"1996","unstructured":"Black DM, Cummings SR, Karpf DB, Cauley JA, Thompson DE et al (1996) Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Lancet 348:1535\u20131541","journal-title":"Lancet"},{"key":"349_CR14","doi-asserted-by":"crossref","first-page":"2077","DOI":"10.1001\/jama.280.24.2077","volume":"280","author":"SR Cummings","year":"1998","unstructured":"Cummings SR, Black DM, Thompson DE, Applegate WB, Barrett-Connor E et al (1998) Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. JAMA 280:2077\u20132082","journal-title":"JAMA"},{"key":"349_CR15","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1046\/j.1532-5415.2002.50102.x","volume":"50","author":"S Levis","year":"2002","unstructured":"Levis S, Quandt SA, Thompson D, Scott J, Schneider DL et al (2002) Alendronate reduces the risk of multiple symptomatic fractures: results from the Fracture Intervention Trial. J Am Geriatr Soc 50:409\u2013415","journal-title":"J Am Geriatr Soc"},{"key":"349_CR16","doi-asserted-by":"crossref","first-page":"4118","DOI":"10.1210\/jc.85.11.4118","volume":"85","author":"DM Black","year":"2000","unstructured":"Black DM, Thompson DE, Bauer DC, Ensrud K, Musliner T et al (2000) Fracture risk reduction with alendronate in women with osteoporosis: the Fracture Interventional Trial. J Clin Endocrinol Metab 85:4118\u20134124","journal-title":"J Clin Endocrinol Metab"},{"key":"349_CR17","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1007\/PL00004171","volume":"9","author":"HA Pols","year":"1999","unstructured":"Pols HA, Felsenberg D, Hanley DA, Stepan J, Munoz-Torres M et al (1999) Multinational, placebo-controlled, randomized trial of the effects of alendronate on bone density and fracture risk in postmenopausal women with low bone mass: results of the FOSIT study. Osteoporos Int 9:461\u2013468","journal-title":"Osteoporos Int"},{"key":"349_CR18","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1210\/jc.85.5.1783","volume":"85","author":"RW Downs Jr","year":"2000","unstructured":"Downs RW Jr, Bell NH, Ettinger MP, Walsh BW, Favus MJ et al (2000) Comparison of alendronate and intranasal calcitonin for treatment of osteoporosis in postmenopausal women. J Clin Endocrinol Metab 85:1783\u20131788","journal-title":"J Clin Endocrinol Metab"},{"key":"349_CR19","doi-asserted-by":"crossref","first-page":"63","DOI":"10.2165\/00044011-200626020-00002","volume":"26","author":"DM Reid","year":"2006","unstructured":"Reid DM, Hosking D, Kendler D, Brandi ML, Wark JD et al (2006) Alendronic acid produces greater effects than risedronic acid on bone density and turnover in postmenopausal women with osteoporosis: results of FACTS\u2014international. Clin Drug Invest 26:63\u201374","journal-title":"Clin Drug Invest"},{"key":"349_CR20","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1359\/JBMR.040325","volume":"19","author":"IC Chestnut","year":"2004","unstructured":"Chestnut IC, Skag A, Christiansen C, Recker R, Stakkestad JA et al (2004) Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis. J Bone Miner Res 19:1241\u20131249","journal-title":"J Bone Miner Res"},{"key":"349_CR21","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1016\/j.bone.2005.05.004","volume":"37","author":"D Felsenberg","year":"2005","unstructured":"Felsenberg D, Miller P, Armbrecht G, Wilson K, Schimmer RC et al (2005) Oral ibandronate significantly reduces the risk of vertebral fractures of greater severity after 1, 2 and 3\u00a0years in postmenopausal women with osteoporosis. Bone (NY) 37:651\u2013654","journal-title":"Bone (NY)"},{"key":"349_CR22","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1185\/030079908X253889","volume":"24","author":"PD Miller","year":"2008","unstructured":"Miller PD, Epstein S, Sedarati F, Reginster JY (2008) Once-monthly oral ibandronate compared with weekly oral alendronate in postmenopausal osteoporosis: results from the head-to-head MOTION study. Curr Med Res Opin 24:207\u2013213","journal-title":"Curr Med Res Opin"},{"key":"349_CR23","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1359\/jbmr.1998.13.11.1747","volume":"13","author":"EG Lufkin","year":"1998","unstructured":"Lufkin EG, Whitaker MD, Nickelsen T, Argueta R, Caplan RH et al (1998) Treatment of established postmenopausal osteoporosis with raloxifene: a randomized trial. J Bone Miner Res 13:1747\u20131754","journal-title":"J Bone Miner Res"},{"key":"349_CR24","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1001\/jama.282.7.637","volume":"282","author":"B Ettinger","year":"1999","unstructured":"Ettinger B, Black DM, Mitlak BH, Knickerbocker RK, Nickelsen T et al (1999) Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. JAMA 282:637\u2013645","journal-title":"JAMA"},{"key":"349_CR25","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1001\/archinte.162.10.1140","volume":"162","author":"M Maricic","year":"2002","unstructured":"Maricic M, Adachi JD, Sarkar S, Wu W, Wong M et al (2002) Early effects of raloxifene on clinical vertebral fractures at 12\u00a0months in postmenopausal women with osteoporosis. Arch Intern Med 162:1140\u20131143","journal-title":"Arch Intern Med"},{"key":"349_CR26","doi-asserted-by":"crossref","first-page":"1955","DOI":"10.1185\/030079905X75032","volume":"21","author":"Y Qu","year":"2005","unstructured":"Qu Y, Wong M, Thiebaud D, Stock JL (2005) The effect of raloxifene therapy on the risk of new clinical vertebral fractures at three and six months: a secondary analysis of the MORE trial. Curr Med Res Opin 21:1955\u20131959","journal-title":"Curr Med Res Opin"},{"key":"349_CR27","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1016\/S8756-3282(03)00241-2","volume":"33","author":"PD Delmas","year":"2003","unstructured":"Delmas PD, Genant HK, Crans GG, Stock JL, Wong M et al (2003) Severity of prevalent vertebral fractures and the risk of subsequent vertebral and nonvertebral fractures: results from the MORE trial. Bone (NY) 33:522\u2013532","journal-title":"Bone (NY)"},{"key":"349_CR28","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1001\/jama.282.14.1344","volume":"282","author":"ST Harris","year":"1999","unstructured":"Harris ST, Watts NB, Genant HK, McKeever CD, Hangartner T et al (1999) Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomised controlled trial. JAMA 282:1344\u20131352","journal-title":"JAMA"},{"key":"349_CR29","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1007\/s001980050010","volume":"11","author":"JY Reginster","year":"2000","unstructured":"Reginster JY, Minne HW, Sorensen OH, Hooper M, Roux C et al (2000) Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group. Osteoporos Int 11:83\u201391","journal-title":"Osteoporos Int"},{"key":"349_CR30","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1007\/s00296-005-0004-4","volume":"26","author":"JD Ringe","year":"2006","unstructured":"Ringe JD, Faber H, Farahmand P, Dorst A (2006) Efficacy of risedronate in men with primary and secondary osteoporosis: results of a 1-year study. Rheumatol Int 26:427\u2013431","journal-title":"Rheumatol Int"},{"key":"349_CR31","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1007\/s00198-003-1401-8","volume":"14","author":"NB Watts","year":"2003","unstructured":"Watts NB, Lindsay R, Li Z, Kasibhatla C, Brown J (2003) Use of matched historical controls to evaluate the anti-fracture efficacy of once-a-week risedronate. Osteoporos Int 14:437\u2013441","journal-title":"Osteoporos Int"},{"key":"349_CR32","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1210\/jc.2002-020400","volume":"88","author":"NB Watts","year":"2003","unstructured":"Watts NB, Josse RG, Hamdy RC, Hughes RA, Manhart MD et al (2003) Risedronate prevents new vertebral fractures in postmenopausal women at high risk. J Clin Endocrinol Metab 88:542\u2013549","journal-title":"J Clin Endocrinol Metab"},{"key":"349_CR33","doi-asserted-by":"crossref","first-page":"1832","DOI":"10.1111\/j.1532-5415.2004.52506.x","volume":"52","author":"S Boonen","year":"2004","unstructured":"Boonen S, McClung MR, Eastell R, El-Haji Fuleihan G, Barton IP et al (2004) Safety and efficacy of risedronate in reducing fracture risk in osteoporotic women aged 80 and older: implications for the use of antiresorptive agents in the old and oldest old. J Am Geriatr Soc 52:1832\u20131839","journal-title":"J Am Geriatr Soc"},{"key":"349_CR34","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1007\/BF03324588","volume":"17","author":"JD Adachi","year":"2005","unstructured":"Adachi JD, Rizzoli R, Boonen S, Li Z, Meredith MP et al (2005) Vertebral fracture risk reduction with risedronate in post-menopausal women with osteoporosis: a meta-analysis of individual patient data. Aging Clin Exp Res 17:150\u2013156","journal-title":"Aging Clin Exp Res"},{"key":"349_CR35","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1185\/030079903125003125","volume":"20","author":"C Roux","year":"2004","unstructured":"Roux C, Seeman E, Eastell R, Adachi J, Jackson RD et al (2004) Efficacy of risedronate on clinical vertebral fractures within six months. Curr Med Res Opin 20:433\u2013439","journal-title":"Curr Med Res Opin"},{"key":"349_CR36","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1056\/NEJM200102013440503","volume":"344","author":"MR McClung","year":"2001","unstructured":"McClung MR, Geusens P, Miller PD, Zippel H, Bensen WG et al (2001) Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group. N Engl J Med 344:333\u2013340","journal-title":"N Engl J Med"},{"key":"349_CR37","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1007\/s00223-003-0042-4","volume":"74","author":"JT Harrington","year":"2004","unstructured":"Harrington JT, Ste-Marie LG, Brandi ML, Civitelli R, Fardellone P et al (2004) Risedronate rapidly reduces the risk for nonvertebral fractures in women with postmenopausal osteoporosis. Calcif Tissue Int 74:129\u2013135","journal-title":"Calcif Tissue Int"},{"key":"349_CR38","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.1001\/archinte.165.15.1737","volume":"165","author":"Y Sato","year":"2005","unstructured":"Sato Y, Kanoko T, Satoh K, Iwamoto J (2005) The prevention of hip fracture with risedronate and ergocalciferol plus calcium supplementation in elderly women with Alzheimer disease. Arch Intern Med 165:1737\u20131742","journal-title":"Arch Intern Med"},{"key":"349_CR39","doi-asserted-by":"crossref","first-page":"142","DOI":"10.18553\/jmcp.2004.10.2.142","volume":"10","author":"NB Watts","year":"2004","unstructured":"Watts NB, Worley K, Solis A, Doyle J, Sheer R (2004) Comparison of risedronate to alendronate and calcitonin for early reduction of nonvertebral fracture risk: results from a managed care administrative claims database. J Manag Care Pharm 10:142\u2013151","journal-title":"J Manag Care Pharm"},{"key":"349_CR40","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1007\/s00198-006-0274-z","volume":"18","author":"SL Silverman","year":"2007","unstructured":"Silverman SL, Watts NB, Delmas PD, Lange JL, Lindsay R (2007) Effectiveness of bisphosphonates on nonvertebral and hip fractures in the first year of therapy: the risedronate and alendronate (REAL) cohort study. Osteoporos Int 18:25\u201334","journal-title":"Osteoporos Int"},{"key":"349_CR41","doi-asserted-by":"crossref","first-page":"445","DOI":"10.2147\/CIA.S8200","volume":"4","author":"T Masud","year":"2009","unstructured":"Masud T, McClung M, Geusens P (2009) Reducing hip fracture risk with risedronate in elderly women with established osteoporosis. Clin Interv Aging 4:445\u2013449","journal-title":"Clin Interv Aging"},{"key":"349_CR42","doi-asserted-by":"crossref","first-page":"1743","DOI":"10.1001\/archinte.165.15.1743","volume":"165","author":"Y Sato","year":"2005","unstructured":"Sato Y, Iwamoto J, Kanoko T, Satoh K (2005) Risedronate sodium therapy for prevention of hip fracture in men 65\u00a0years or older after stroke. Arch Intern Med 165:1743\u20131748","journal-title":"Arch Intern Med"},{"key":"349_CR43","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1212\/01.WNL.0000152871.65027.76","volume":"64","author":"Y Sato","year":"2005","unstructured":"Sato Y, Iwamoto J, Kanoko T, Satoh K (2005) Risedronate therapy for prevention of hip fracture after stroke in elderly women. Neurology 64:811\u2013816","journal-title":"Neurology"},{"key":"349_CR44","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1212\/01.wnl.0000257089.50476.92","volume":"68","author":"Y Sato","year":"2007","unstructured":"Sato Y, Honda Y, Iwamoto J (2007) Risedronate and ergocalciferol prevent hip fracture in elderly men with Parkinson disease. Neurology 68:911\u2013915","journal-title":"Neurology"},{"key":"349_CR45","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1056\/NEJMoa022436","volume":"350","author":"PJ Meunier","year":"2004","unstructured":"Meunier PJ, Roux C, Seeman E, Ortolani S, Badurski JE et al (2004) The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis. N Engl J Med 350:459\u2013468","journal-title":"N Engl J Med"},{"key":"349_CR46","doi-asserted-by":"crossref","first-page":"2816","DOI":"10.1210\/jc.2004-1774","volume":"90","author":"JY Reginster","year":"2005","unstructured":"Reginster JY, Seeman E, De Vernejoul MC, Adami S, Compston J et al (2005) Strontium ranelate reduces the risk of nonvertebral fractures in postmenopausal women with osteoporosis: treatment of peripheral osteoporosis (TROPOS) study. J Clin Endocrinol Metab 90:2816\u20132822","journal-title":"J Clin Endocrinol Metab"},{"key":"349_CR47","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1359\/jbmr.060404","volume":"21","author":"E Seeman","year":"2006","unstructured":"Seeman E, Vellas B, Benhamou C, Aquino JP, Semler J et al (2006) Strontium ranelate reduces the risk of vertebral and nonvertebral fractures in women eighty years of age and older. J Bone Miner Res 21:1113\u20131120","journal-title":"J Bone Miner Res"},{"key":"349_CR48","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1056\/NEJMoa067312","volume":"356","author":"DM Black","year":"2007","unstructured":"Black DM, Delmas PD, Eastell R, Reid IR, Boonen S et al (2007) Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med 356:1809\u20131822","journal-title":"N Engl J Med"},{"key":"349_CR49","doi-asserted-by":"crossref","first-page":"1799","DOI":"10.1056\/NEJMoa074941","volume":"357","author":"KW Lyles","year":"2007","unstructured":"Lyles KW, Col\u00f3n-Emeric CS, Magaziner JS, Adachi JD, Pieper CF et al (2007) Zoledronic acid and clinical fractures and mortality after hip fracture. N Engl J Med 357:1799\u20131809","journal-title":"N Engl J Med"},{"key":"349_CR50","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1111\/j.1532-5415.2009.02673.x","volume":"58","author":"S Boonen","year":"2010","unstructured":"Boonen S, Black DM, Col\u00f3n-Emeric CS, Eastell R, Magaziner JS et al (2010) Efficacy and safety of a once-yearly intravenous zoledronic acid 5\u00a0mg for fracture prevention in elderly postmenopausal women with osteoporosis aged 75 and older. J Am Geriatr Soc 58:292\u2013299","journal-title":"J Am Geriatr Soc"},{"key":"349_CR51","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1007\/s00774-009-0144-9","volume":"28","author":"A Sontag","year":"2010","unstructured":"Sontag A, Krege JH (2010) First fractures among postmenopausal women with osteoporosis. J Bone Miner Metab 28:485\u2013488","journal-title":"J Bone Miner Metab"}],"container-title":["Journal of Bone and Mineral Metabolism"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00774-012-0349-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00774-012-0349-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00774-012-0349-1","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,16]],"date-time":"2022-01-16T10:47:23Z","timestamp":1642330043000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00774-012-0349-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,5,29]]},"references-count":51,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2012,9]]}},"alternative-id":["349"],"URL":"https:\/\/doi.org\/10.1007\/s00774-012-0349-1","relation":{},"ISSN":["0914-8779","1435-5604"],"issn-type":[{"value":"0914-8779","type":"print"},{"value":"1435-5604","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,5,29]]}}}